• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    S&P Biotech SPDR (NY: XBI )

    103.01 +0.57 (+0.56%)
    Official Closing Price Updated: 4:10 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about S&P Biotech SPDR

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    7 Best Biotech Stocks to Buy in July 2022
    The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
    Via InvestorPlace
    3 Biotech Stocks to Sell Now
    These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead. 
    Via InvestorPlace
    Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
    The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
    Via Benzinga
    3 Stocks to Sell Now
    Equities suffer from the highest inflation readings of a generation. Here's a trio of S&P 500 stocks to sell before things get worse. 
    Via InvestorPlace
    7 Biotech Stocks With Key Catalysts Coming in July
    Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
    Via InvestorPlace
    U.S. Weekly FundFlows Insight Report: Sector-Energy Funds Report $1.3 Billion in Outflows, Fourth Largest on Record
    During fund-flows week ended June 22, 2022, investors were overall net sellers of fund assets (including both conventional funds and ETFs) for the second straight week, withdrawing a net $20.1... 
    Via Talk Markets
    3 Beaten-Down ETFs to Buy Before They Rebound
    The charts are improving for these fallen angels, and that makes them all top ETFs to buy for the back half of the year. 
    Via InvestorPlace
    “Should’ve Been Me” Stock Market (And Sentiment Results)
    In this week’s AAII Sentiment Survey result, bullish percent ticked down to 18.2% this week from 19.4% last week. 
    Via Talk Markets
    Option Bears Reloading as Bulls Feeling Spry
    As the bulls have their moment, the bears are adding bearish options positions and rolling up into the strength. 
    Via Talk Markets
    Stock Drop On June 16, But A Rally May Be Coming After Options Expiration
    Another miserable day for stocks, with the S&P 500 dropping 3.25% 
    Via Talk Markets
    Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
    Crispr and Vertex tested their gene-edited drug in two blood diseases. 
    Via Investor's Business Daily
    “Chip Shot” Stock Market (And Sentiment Results)
    Chips are the key to the economy/inflation moving forward. They are also the key to one of our major new positions in an auto-supplier 
    Via Talk Markets
    3 Biotech Stocks to Buy Before They Boom
    It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
    Via InvestorPlace
    Again, Buy ‘Em
    Today we discuss again why it’s time to start adding back risk. We cover the major breadth thrusts that fired, some great monthly charts, and more. 
    Via Talk Markets
    As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
    The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data... 
    Via Benzinga
    PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
    Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
    Via Benzinga
    This Biotech Looks Good With Increased M&A activity
    Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for... 
    Via Talk Markets
    The “Mystery Liquidator Revealed” Stock Market (And Sentiment Results)
    In this week’s AAII Sentiment Survey result, Bullish Percent ticked up a hair to 26% this week from 24.3% last week. Bearish Percent rose to 50.4% from 49%. 
    Via Talk Markets
    Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
    Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
    Via Talk Markets
    When Will The Stock Market Stop Falling?
    Stocks have fallen dramatically just this past week, is a bottom near? 
    Via Talk Markets
    Stocks Tank On May 11 With No Bottom In Sight
    Despite the sharp decline, the VIX finished down on the day at 32.5. It tells us there was “real” selling in the market today. 
    Via Talk Markets
    7 Biotech Stocks With Key Catalysts for May
    The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
    Via InvestorPlace
    Should Biotech Be On The Critical List?
    The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
    Via Talk Markets
    “Threading The Needle” Stock Market (And Sentiment Results)
    Two weeks ago AAII sentiment survey dropped to a 30 year low at 15.8% bullish. Last week it ticked up modestly to 16.4%. 
    Via Talk Markets
    7 Monster Stock Market Predictions For The Week Of April 25
    The week ending April 22 was brutal. The S&P 500 fell by nearly 2.75%, but things were much worse than that. Powell unleashed hell when he noted that a 50 bps rate hike was on the table for the FOMC... 
    Via Talk Markets
    The “magic Chart” Stock Market (And Sentiment Results)
    We have now come to a point Where the market has priced in more rate hikes than are likely to occur. 
    Via Talk Markets
    4 Undervalued Biotech Stocks to Add to Your Buy List
    These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
    Via InvestorPlace
    Healthcare Stocks Lead the Way Up as the Market Fades
    With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions. 
    Via Talk Markets
    Recession Fears are Creating a Golden Opportunity for Biotech Stocks
    Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
    Via InvestorPlace
    Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
    Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
    Via InvestorPlace
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.